Italy Cell And Gene Therapy Manufacturing Market Size & Outlook
Italy cell and gene therapy manufacturing market, 2018-2030 (US$M)
Related Markets
Italy makes a significant contribution to the global cell and gene therapy manufacturing market with development of 3 out of 10 gene therapy products approved in Europe. This active engagement of the country in this space is considered a key factor for market growth in the country. Besides, companies operating in the country are forming partnerships for gene therapy manufacturing. For instance, in July 2020 MolMed S.p.A extended its collaboration with UK-based Orchard Therapeutics for gene therapy manufacturing. As a part of this collaboration, the Italian company will support the latter company’s development and manufacturing of vectors & drug products. MolMed S.p.A. is the first company with GMP authorization for cell and gene therapy manufacturing in Europe. In addition, in June 2020, Rigenerand—an Italian biotech company—received regulatory approval from the Italian Medicine Authority for gene therapy production in Italy. Presence of such companies is expected to further drive market growth in the country. On the other hand, companies such as Anemocyte are representing the country in conferences like Phacilitate Leaders World 2020. This company is the first Biotech Manufacturing Organization (BMO) that operates in the life sciences sector. cell and gene therapy manufacturing market highlights
- The Italy cell and gene therapy manufacturing market generated a revenue of USD 260.3 million in 2022 and is expected to reach USD 1,726.3 million by 2030.
- The Italy market is expected to grow at a CAGR of 26.7% from 2023 to 2030.
- In terms of segment, cell therapy was the largest revenue generating therapy type in 2022.
- Gene Therapy is the most lucrative therapy type segment registering the fastest growth during the forecast period.
Cell and gene therapy manufacturing market data book summary
| Market revenue in 2022 | USD 260.3 million |
| Market revenue in 2030 | USD 1,726.3 million |
| Growth rate | 26.7% (CAGR from 2022 to 2030) |
| Largest segment | Cell therapy |
| Fastest growing segment | Gene Therapy |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gene Therapy, Cell Therapy |
| Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
Other key industry trends
- In terms of revenue, Italy accounted for 3.6% of the global cell and gene therapy manufacturing market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, France cell and gene therapy manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- France is the fastest growing regional market in Europe and is projected to reach USD 3,354.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy Manufacturing Market Scope
Cell And Gene Therapy Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Italy cell and gene therapy manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 57.36% in 2022. Horizon Databook has segmented the Italy cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Italy makes a significant contribution to the global cell and gene therapy manufacturing market with development of 3 out of 10 gene therapy products approved in Europe. This active engagement of the country in this space is considered a key factor for market growth in the country.
Besides, companies operating in the country are forming partnerships for gene therapy manufacturing. For instance, in July 2020 MolMed S.p.A extended its collaboration with UK-based Orchard Therapeutics for gene therapy manufacturing.
As a part of this collaboration, the Italian company will support the latter company’s development and manufacturing of vectors & drug products. MolMed S.p.A. is the first company with GMP authorization for cell and gene therapy manufacturing in Europe.
Reasons to subscribe to Italy cell and gene therapy manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Italy cell and gene therapy manufacturing market databook
-
Our clientele includes a mix of cell and gene therapy manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy cell and gene therapy manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Italy cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Italy cell and gene therapy manufacturing market size, by therapy type, 2018-2030 (US$M)
Italy Cell And Gene Therapy Manufacturing Market Outlook Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
